Financial Summary (Consolidated) for the Second Quarter of the Fiscal Year Ending December 2026 (Japanese Standards)

Overview of results

For the second quarter of the fiscal year ending December 2026, the consolidated results show net sales of 10,434 million yen, operating income 922 million yen, ordinary income 1,279 million yen, and net income attributable to owners of the parent of 663 million yen, all down versus the previous year. By segment, the Pharmaceutical/Dispensing System segment saw declines in sales and profits, the Medical System segment saw a decline in sales and losses, the Nursing Care/Welfare System segment saw increases in sales but continued losses, and Others saw a decrease in sales. The impact of the newly consolidated subsidiary Condact may result in goodwill accounting.

Financial position and dividends

Total assets amount to 26,776 million yen, net assets to 19,996 million yen, and the equity ratio stands at 74.3%. Due to decreases in cash and deposits, current assets are 11,792 million yen, while liabilities, including changes in long-term borrowings, total 6,779 million yen. The annual dividend plan remains unchanged versus the fiscal year ending December 2025; the document notes the payment start date for the interim dividend in the fiscal year ending December 2026.